DDX3X and colorectal cancer: In the present study, we showed that DDX3 is overexpressed in 39% of colorectal cancers and that inhibition of DDX3 results in reduced Wnt signaling and a G1 arrest, making DDX3 an attractive therapeutic target in these cancers.